Mitali Singhal
Mitali Singhal has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jacobo Elies
Institute of Cancer Therapeutics, University of Bradford, Bradford, Richmond Rd, Bradford BD7 1DP, United Kingdom
2 shared publications - Maria G. Katsikogianni
School of Chemistry and Biosciences, University of Bradford, Bradford BD7 1DP, UK
2 shared publications - Alexander Surtees
School of Archaeological and Forensic Sciences, University of Bradford, Bradford BD7 1DP, UK
1 shared publication - Amalia Ruiz
Institute of Cancer Therapeutics, University of Bradford, Bradford, Richmond Rd, Bradford BD7 1DP, United Kingdom
1 shared publication Amalia Ruiz Estrada
University of Bradford, Bradford, United Kingdom
1 shared publication- Balaji Lakavath
Central Research Laboratory for Biomedical Research, Vinayaka Mission’s Kirupananda Variyar Medical College & Hospitals, Vinayaka Mission’s Research Foundation (Deemed to be University), Salem 636308, Tamil Nadu, India
1 shared publication
Latest Publications
- Open Access
- 31 October 2026
- Published by MDPI AG in Breast Cancer Research and Care
- Vol. 1 (1) , 4
From Molecular Resolution to Clinical Decision in Triple-Negative Breast Cancer: A Time-Aware Framework for Multi-Omic Precision Oncology
Triple-negative breast cancer (TNBC) is a receptor-defined diagnosis encompassing genomic, transcriptional, epigenetic, proteomic, metabolic, cellular and spatial heterogeneity. Although transcriptomic classifications established biologically interpretable TNBC subtypes, multi-omic, single-cell and spatial studies show that tumour states may coexist within the same lesion and evolve under treatment pressure. The central translational question is therefore not simply how to generate higher-resolution molecular maps, but which biological layer should be measured, at what clinical time point, and whether that information can change patient-level decisions. This narrative review proposes a time-aware resolution-to-decision framework for TNBC precision oncology. We examine how genomics defines molecular potential; transcriptomics and epigenomics capture active and plastic cellular programmes; proteomics and metabolomics provide functional pathway readouts; and single-cell and spatial approaches resolve cellular and anatomical context. We then evaluate circulating tumour DNA as a longitudinal biomarker for molecular residual disease and tumour evolution, distinguishing strong prognostic evidence from still-unproven treatment-intervention utility. Using the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) as a reference for genomic actionability, we distinguish established biomarkers from context-dependent markers and investigational multi-omic signatures, while noting that several recent therapeutic advances required little or no molecular selection. Molecular profiling should be judged by biological resolution, disease time point and evidence maturity rather than by technological complexity alone.
- 31 October 2026
- Published by MDPI AG in Breast Cancer Research and Care
- Vol. 1 (1) , 4
Open AccessFrom Molecular Resolution to Clinical Decision in Triple-Negative Breast Cancer: A Time-Aware Framework for Multi-Omic Precision Oncology
Triple-negative breast cancer (TNBC) is a receptor-defined diagnosis encompassing genomic, transcriptional, epigenetic, proteomic, metabolic, cellular and spatial heterogeneity. Although transcriptomic classifications established biologically interpretable TNBC subtypes, multi-omic, single-cell and spatial studies show that tumour states may coexist within the same lesion and evolve under treatment pressure. The central translational question is therefore not simply how to generate higher-resolution molecular maps, but which biological layer should be measured, at what clinical time point, and whether that information can change patient-level decisions. This narrative review proposes a time-aware resolution-to-decision framework for TNBC precision oncology. We examine how genomics defines molecular potential; transcriptomics and epigenomics capture active and plastic cellular programmes; proteomics and metabolomics provide functional pathway readouts; and single-cell and spatial approaches resolve cellular and anatomical context. We then evaluate circulating tumour DNA as a longitudinal biomarker for molecular residual disease and tumour evolution, distinguishing strong prognostic evidence from still-unproven treatment-intervention utility. Using the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) as a reference for genomic actionability, we distinguish established biomarkers from context-dependent markers and investigational multi-omic signatures, while noting that several recent therapeutic advances required little or no molecular selection. Molecular profiling should be judged by biological resolution, disease time point and evidence maturity rather than by technological complexity alone.
- Open Access
- 18 November 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (11) , 1467
Formulation, Characterisation, and Biocompatibility Assessment of Rifampicin-Loaded Poly(d,l-lactide-co-glycolide) Composites for Local Treatment of Orthopaedic and Wound Infections
Background/Objectives: The escalating challenge of antimicrobial resistance (AMR) necessitates the development of targeted antibiotic delivery platforms, minimising systemic administration. Polymer-based drug delivery emerges as a promising solution, ensuring sustained release and prolonged efficacy of bioactive compounds, ensuring long-term efficacy. Methods: This study focuses on encapsulating rifampicin (RIF), a key antibiotic for orthopaedic and wound-related infections, within Poly(d,l-lactide-co-glycolide) (PLGA), a biodegradable polymer, through solvent casting, to formulate a PLGA-RIF composite membrane. Comprehensive characterisation, employing Fourier-transformed infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), thermal analysis and X-ray Diffraction (XRD), confirmed the integrity of both the starting and produced materials. UV-Vis spectroscopy revealed a controlled drug release profile over 21 days in various media, with the chosen media influencing the drug release, notably the tryptic soya broth (TSB) caused the highest release. The quantitative assessment of the antimicrobial efficacy of the developed PLGA-RIF composite was conducted by measuring the size of the inhibition zones against both Gram-negative and Gram-positive bacteria. Results: The results confirmed the composite’s potential as a robust antibacterial biomaterial, demonstrating a rapid and effective antibacterial response. Cytocompatibility tests incorporated human fibroblast and osteoblast-like cell lines and demonstrated that the RIF:PLGA (1:8) formulation maintained eukaryotic cell viability, indicating the composite’s potential for targeted medical applications in combating bacterial infections with minimal systemic impact. Conclusions: This study presents the significance of investigating drug release within appropriate and relevant physiological media. A key novelty of this work therefore lies in the exploration of drug release dynamics across different media, allowing for a comprehensive understanding of how varying physiological conditions may influence drug release and its effect on biological responses.
- 18 November 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (11) , 1467
Open AccessFormulation, Characterisation, and Biocompatibility Assessment of Rifampicin-Loaded Poly(d,l-lactide-co-glycolide) Composites for Local Treatment of Orthopaedic and Wound Infections
Background/Objectives: The escalating challenge of antimicrobial resistance (AMR) necessitates the development of targeted antibiotic delivery platforms, minimising systemic administration. Polymer-based drug delivery emerges as a promising solution, ensuring sustained release and prolonged efficacy of bioactive compounds, ensuring long-term efficacy. Methods: This study focuses on encapsulating rifampicin (RIF), a key antibiotic for orthopaedic and wound-related infections, within Poly(d,l-lactide-co-glycolide) (PLGA), a biodegradable polymer, through solvent casting, to formulate a PLGA-RIF composite membrane. Comprehensive characterisation, employing Fourier-transformed infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), thermal analysis and X-ray Diffraction (XRD), confirmed the integrity of both the starting and produced materials. UV-Vis spectroscopy revealed a controlled drug release profile over 21 days in various media, with the chosen media influencing the drug release, notably the tryptic soya broth (TSB) caused the highest release. The quantitative assessment of the antimicrobial efficacy of the developed PLGA-RIF composite was conducted by measuring the size of the inhibition zones against both Gram-negative and Gram-positive bacteria. Results: The results confirmed the composite’s potential as a robust antibacterial biomaterial, demonstrating a rapid and effective antibacterial response. Cytocompatibility tests incorporated human fibroblast and osteoblast-like cell lines and demonstrated that the RIF:PLGA (1:8) formulation maintained eukaryotic cell viability, indicating the composite’s potential for targeted medical applications in combating bacterial infections with minimal systemic impact. Conclusions: This study presents the significance of investigating drug release within appropriate and relevant physiological media. A key novelty of this work therefore lies in the exploration of drug release dynamics across different media, allowing for a comprehensive understanding of how varying physiological conditions may influence drug release and its effect on biological responses.
- Open Access
- 18 October 2024
- Published by IntechOpen
Comparative Analysis of Cytotoxicity Assays, from Traditional to Modern Approaches
This chapter will provide a comprehensive comparative analysis of various cytotoxicity assays, including traditional methods like the MTT assay and modern approaches such as the ATP assay and flow cytometry. Each method will be examined in detail, covering its principle, procedure, advantages, limitations, and specific applications in cytotoxicity testing. Additionally, the chapter will address the interconnectivity of different cell death pathways—apoptosis, autophagy, and necrosis—and discuss how various assays can be used in combination to achieve a more accurate and holistic assessment of cell viability and death mechanisms. Practical guidelines will be provided to help researchers select the most appropriate assay based on their specific experimental requirements, cell types, and research objectives. By offering a comparative framework, this chapter aims to equip researchers with the knowledge needed to enhance the accuracy and reliability of their cytotoxicity assessments, ultimately advancing toxicological research and drug development.
- 18 October 2024
- Published by IntechOpen
Open AccessComparative Analysis of Cytotoxicity Assays, from Traditional to Modern Approaches
This chapter will provide a comprehensive comparative analysis of various cytotoxicity assays, including traditional methods like the MTT assay and modern approaches such as the ATP assay and flow cytometry. Each method will be examined in detail, covering its principle, procedure, advantages, limitations, and specific applications in cytotoxicity testing. Additionally, the chapter will address the interconnectivity of different cell death pathways—apoptosis, autophagy, and necrosis—and discuss how various assays can be used in combination to achieve a more accurate and holistic assessment of cell viability and death mechanisms. Practical guidelines will be provided to help researchers select the most appropriate assay based on their specific experimental requirements, cell types, and research objectives. By offering a comparative framework, this chapter aims to equip researchers with the knowledge needed to enhance the accuracy and reliability of their cytotoxicity assessments, ultimately advancing toxicological research and drug development.
- Open Access
- 26 February 2024
- Published by MDPI AG in Applied Sciences
- Vol. 14 (5) , 1902
Encapsulation and Delivery of Mitoxantrone Using Zirconium-Based Metal–Organic Frameworks (MOFs) and Their Cytotoxic Potential in Breast Cancer Cells
Mitoxantrone (MTX) is a drug employed in breast cancer treatment, but its application is largely limited due to side effects. A controlled delivery approach can potentially reduce the side effects. In this study, two zirconium (Zr)-based MOFs, UiO-66 and UiO-66-NH2, were studied for a more controlled delivery of MTX with a 40% and 21% loading capacity, respectively. Characterisation via powder X-ray diffraction, thermogravimetric analysis, Fourier transform infrared spectrometry, scanning electron microscopy, and dynamic light scattering confirmed the integrity of structure post-MTX loading. UV–vis spectrophotometry revealed distinctive release profiles, with UiO-66-MTX exhibiting a 25% cumulative release after 96 h in water and 120 h in PBS +10% FBS. UiO-66-NH2-MTX displayed a more sustained release, reaching 62% in water and 47% in PBS +10% FBS after 168 h. The interaction between MTX and the MOFs was also proposed based on computational modelling, suggesting a stronger interaction of UiO-66NH2 and MTX, and an optimised interaction of MTX in the tetrahedral and octahedral pores of the MOFs. The study also reports the release profile of the drug and antiproliferative activity against a panel of breast cancer cell lines (MDA-MB-231, MDA-MB-468, and MCF7) and a normal breast epithelial cell line (MCF10A). MTX-encapsulated MOFs were thoroughly characterised, and their biological activity was assessed in vitro. MTT cell viability assay indicated a higher IC50 value for MTX-loaded MOFs compared to free MTX in physiological conditions, albeit with a slower release profile. These findings suggest the potential of these MTX-loaded MOFs as an alternative avenue for formulation to mitigate side effects.
- 26 February 2024
- Published by MDPI AG in Applied Sciences
- Vol. 14 (5) , 1902
Open AccessEncapsulation and Delivery of Mitoxantrone Using Zirconium-Based Metal–Organic Frameworks (MOFs) and Their Cytotoxic Potential in Breast Cancer Cells
Mitoxantrone (MTX) is a drug employed in breast cancer treatment, but its application is largely limited due to side effects. A controlled delivery approach can potentially reduce the side effects. In this study, two zirconium (Zr)-based MOFs, UiO-66 and UiO-66-NH2, were studied for a more controlled delivery of MTX with a 40% and 21% loading capacity, respectively. Characterisation via powder X-ray diffraction, thermogravimetric analysis, Fourier transform infrared spectrometry, scanning electron microscopy, and dynamic light scattering confirmed the integrity of structure post-MTX loading. UV–vis spectrophotometry revealed distinctive release profiles, with UiO-66-MTX exhibiting a 25% cumulative release after 96 h in water and 120 h in PBS +10% FBS. UiO-66-NH2-MTX displayed a more sustained release, reaching 62% in water and 47% in PBS +10% FBS after 168 h. The interaction between MTX and the MOFs was also proposed based on computational modelling, suggesting a stronger interaction of UiO-66NH2 and MTX, and an optimised interaction of MTX in the tetrahedral and octahedral pores of the MOFs. The study also reports the release profile of the drug and antiproliferative activity against a panel of breast cancer cell lines (MDA-MB-231, MDA-MB-468, and MCF7) and a normal breast epithelial cell line (MCF10A). MTX-encapsulated MOFs were thoroughly characterised, and their biological activity was assessed in vitro. MTT cell viability assay indicated a higher IC50 value for MTX-loaded MOFs compared to free MTX in physiological conditions, albeit with a slower release profile. These findings suggest the potential of these MTX-loaded MOFs as an alternative avenue for formulation to mitigate side effects.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 4386
Abstract 4386: Comparison of cytotoxicity of anthracycline based antineoplastic drugs in breast cancer
Mitoxantrone (MTX) is used for the chemotherapeutic treatment of breast cancer, but it has a dose-limiting cardiotoxicity. One of the mechanisms of MTX cytotoxicity is by inhibiting the topoisomerase II enzyme, which is crucial for maintaining cellular processes like replication. The aim of the study is to investigate if an alternative analog of MTX, named KP71 would be a suitable antineoplastic drug with reduced cardiovascular side effects. Cytotoxicity of both drugs in breast cancer cell lines MDA-MB-468, MDA-MB-231, MCF7, the non-neoplastic breast cell line MCF10, cardiac human fibroblasts (HFB), and human umbilical vein endothelial cells (HUVEC) was assessed by MTT at 96h. The IC50 values (nM) for MTX/KP71 were as shown in table below. DNA decatenation assay demonstrated topoisomerase II inhibition with values of IC50 = 2.9/12.3 µM for topoisomerase IIα, and 2.1/7.0 µM for topoisomerase IIβ for MTX/KP71 respectively. Western blotting showed DNA damage by the gradation in γH2AX expression at different concentrations of MTX and KP71 at 6 h and 24 h treatment. KP71 was found to retain the ability to inhibit the proliferation of neoplastic cell lines in vitro with a slower profile of cytotoxicity on non-neoplastic cell lines as compared to MTX. KP71 partly exerted cytotoxicity by damaging DNA and inhibiting topoisomerase II enzyme activity. Organotypic HFB-HUVEC co-cultures were used to investigate the effects of anthracycline drugs in angiogenesis. Although both drugs reduced the number of tubules (and branches) compared to control (absence of drug), there were not significant differences between MTX and KP71. Citation Format: Mitali Singhal, Jacobo Elies Gomez, Sanjit Nayak, Kirsten Riches Suman, Amalia Ruiz Estrada. Comparison of cytotoxicity of anthracycline based antineoplastic drugs in breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4386.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 4386
Abstract 4386: Comparison of cytotoxicity of anthracycline based antineoplastic drugs in breast cancer
Mitoxantrone (MTX) is used for the chemotherapeutic treatment of breast cancer, but it has a dose-limiting cardiotoxicity. One of the mechanisms of MTX cytotoxicity is by inhibiting the topoisomerase II enzyme, which is crucial for maintaining cellular processes like replication. The aim of the study is to investigate if an alternative analog of MTX, named KP71 would be a suitable antineoplastic drug with reduced cardiovascular side effects. Cytotoxicity of both drugs in breast cancer cell lines MDA-MB-468, MDA-MB-231, MCF7, the non-neoplastic breast cell line MCF10, cardiac human fibroblasts (HFB), and human umbilical vein endothelial cells (HUVEC) was assessed by MTT at 96h. The IC50 values (nM) for MTX/KP71 were as shown in table below. DNA decatenation assay demonstrated topoisomerase II inhibition with values of IC50 = 2.9/12.3 µM for topoisomerase IIα, and 2.1/7.0 µM for topoisomerase IIβ for MTX/KP71 respectively. Western blotting showed DNA damage by the gradation in γH2AX expression at different concentrations of MTX and KP71 at 6 h and 24 h treatment. KP71 was found to retain the ability to inhibit the proliferation of neoplastic cell lines in vitro with a slower profile of cytotoxicity on non-neoplastic cell lines as compared to MTX. KP71 partly exerted cytotoxicity by damaging DNA and inhibiting topoisomerase II enzyme activity. Organotypic HFB-HUVEC co-cultures were used to investigate the effects of anthracycline drugs in angiogenesis. Although both drugs reduced the number of tubules (and branches) compared to control (absence of drug), there were not significant differences between MTX and KP71. Citation Format: Mitali Singhal, Jacobo Elies Gomez, Sanjit Nayak, Kirsten Riches Suman, Amalia Ruiz Estrada. Comparison of cytotoxicity of anthracycline based antineoplastic drugs in breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4386.